My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search
Jindal Drilling & Industries standalone net profit declines 3.66% in the June 2016 quarter

Jindal Drilling & Industries standalone net profit declines 3.66% in the June 2016 quarter

Sep 14,2016

Net profit of Jindal Drilling & Industries declined 3.66% to Rs 9.48 crore in the quarter ended June 2016 as against Rs 9.84 crore during the previous quarter ended June 2015. Sales rose 11.24% to Rs 92.66 crore in the quarter ended June 2016 as against Rs 83.30 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales92.6683.3011
OPM %9.8912.74-
PBDT14.5518.68-22
PBT12.0915.01-19
NP9.489.84-4

Powered by Capital Market - Live News

Jubilant Life Sciences gains after good Q2 earnings
Oct 28,2016

The result was announced after market hours yesterday, 27 October 2016.

Meanwhile, the BSE Sensex was up 23.44 points, or 0.08%, to 27,939.34.

On BSE, so far 1.57 lakh shares were traded in the counter, compared with average daily volume of 2.96 lakh shares in the past one quarter. The stock hit a high of Rs 698 and a low of Rs 637.50 so far during the day. The stock hit a record high of Rs 700.90 on 19 October 2016. The stock hit a 52-week low of Rs 272.50 on 20 January 2016. The stock had outperformed the market over the past 30 days till 27 October 2016, rising 2.68% compared with 1.33% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 93.73% as against Sensexs 0.48% decline.

The large-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.

Jubilant Life Sciences consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) rose 5 % to Rs Rs 345 crore in Q2 September 2016 over Q2 September 2015. EBITDA margins were reported at 24.3% in Q2 September 2016 compareed with 22% in Q2 September 2015.

Commenting on the Companys performance, Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said that the company expects to deliver improved performance in the coming quarters, backed by new product launches in our Generics and Specialty businesses.

In its outlook, the company said that in the second half of the financial year ending March 2017, it is confident of improving its performance. In pharmaceuticals segment, profitability is expected to be higher on account of new product launches in generics and specialty products, growth in rest of the world (ROW) business and ramp-up of operations and new customer acquisitionsin CMO of Sterile Injectables. The companys focus will be on generating operating cash in life science ingredients by retrofitting plants for better capacity utilization with new product introductions. In drug discovery solutions, the focus will be on revenue growth aided by strong pipeline and onboarding of new customers. The compnays endeavours to reduce debt through operating cash flow and to improve key financial ratios will continue.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Powered by Capital Market - Live News

Reliance Communications gets High Court approval for scheme of arrangement
Oct 28,2016

Reliance Communications announced that the that Honble High Court of Judicature at Bombay on 27 October 2016 sanctioned the Scheme of Arrangement between the Company and Reliance Telecom (RTL), a wholly owned subsidiary of the Company, for demerger of Telecom Undertaking consisting of 5 License Service Area of RTL into the Company (Scheme).

Powered by Capital Market - Live News

Bajaj Finserv gains after robust Q2 result
Oct 28,2016

The result was announced after market hours yesterday, 27 October 2016.

Meanwhile, the S&P BSE Sensex was up 30.91 points or 0.11% at 27,946.81

On BSE, so far 44,000 shares were traded in the counter as against average daily volume of 21,772 shares in the past one quarter. The stock hit a high of Rs 3,400 and a low of Rs 3,289 so far during the day. The stock had hit a record high of Rs 3,443 on 19 October 2016. The stock had hit a 52-week low of Rs 1,575.70 on 23 February 2016. The stock had outperformed the market over the past 30 days till 27 October 2016, rising 1.14% compared with 1.33% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 20.15% as against Sensexs 0.48% decline.

The large-cap stock has equity capital of Rs 79.57 crore. Face value per share is Rs 5.

Bajaj Finserv is the holding company for the various financial services businesses under the Bajaj group. The company participates in financing business through its 57.28% holding in Bajaj Finance and in the protection business through its 74% holding in Bajaj Allianz General Insurance Company (BAGIC) and Bajaj Allianz Life Insurance Company (BALIC). Bajaj Finserv holds 92.50 lakh warrants convertible into equity shares of Bajaj Finance on or before 1 December 2016. When exercised, the holding of Bajaj Finserv in Bajaj Finance will increase from 57.28% to 58%.

Powered by Capital Market - Live News

Cupid fixes record date for interim dividend
Oct 28,2016

Cupid has fixed 09 November 2016 as the Record Date for the purpose of Payment of Interim Dividend.

Further, the payment of dividend shall be made on 22 November 2016.

Powered by Capital Market - Live News

Indiabulls Real Estate allots equity shares
Oct 28,2016

Indiabulls Real Estate announced that on 27 October 2016, the Company, has issued and allotted 1,35,600 (One Lac Thirty Five Thousand Six Hundred) Equity shares of face value Rs. 2/- each, to eligible employees upon exercise of options vested in their favour under Indiabulls Real Estate Limited - Employees Stock Option Scheme 2010.

Consequent to the said allotment, the paid-up Equity share capital of the Company stands increased from Rs. 101,30,57,478/- divided into 50,65,28,739 Equity shares of face value Rs. 2/- each, to Rs. 101,33,28,678/- divided into 50,66,64,339 Equity shares of face value Rs. 2/- each.

Powered by Capital Market - Live News

Indiabulls Housing Finance allots equity shares
Oct 28,2016

Indiabulls Housing Finance announced that on 27 October 2016, the Company, has issued and allotted 14,24,301 (Fourteen Lac Twenty Four Thousand Three Hundred and One only) Equity shares of face value Rs. 2/- each, to eligible employees upon exercise of options vested in their favour under different ESOP Schemes of the Company.

Consequent to the said allotment, the paid-up Equity Share Capital of the Company stands increased to INR 84,67,02,744/- divided into 42,33,51,372 Equity Shares of face value Rs. 2/- each.

Powered by Capital Market - Live News

Glenmark Pharma gains after decent Q2 results
Oct 28,2016

The result was announced after market hours yesterday, 27 October 2016.

Meanwhile, the BSE Sensex was up 63.64 points, or 0.23%, to 27,979.54.

On BSE, so far 21,000 shares were traded in the counter, compared with average daily volume of 65,000 shares in the past one quarter. The stock hit a high of Rs 938 and a low of Rs 911 so far during the day. The stock hit a 52-week high of Rs 1,001.65 on 30 October 2015. The stock hit a 52-week low of Rs 671.50 on 12 February 2016. The stock had underperformed the market over the past 30 days till 27 October 2016, falling 4.33% compared with 1.33% decline in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 5.39% as against Sensexs 0.48% decline.

The large-cap company has equity capital of Rs 28.22 crore. Face value per share is Re 1.

Glenmark Pharmaceuticals consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) rose 11.15% to Rs Rs 448.76 crore in Q2 September 2016 over Q2 September 2015.

Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals said that the US, India, rest of the world (ROW) and the active pharma ingredients (API) business have done well in the first half of the financial year. The strong growth witnessed by the US business is on account of a number of product approvals received by the organization over the last 18 months. The overall business has gained good traction especially across key geographies. The entire emerging markets business ex India which got severely hit in the past few years on account of currencies is also recuperating well.

Sales for the formulation business in India rose 10.91% to Rs 674.93 crore in Q2 September 2016 over Q2 September 2015. Glenmark Pharmaceuticals Inc., U.S.A. registered revenue from the sale of finished dosage formulations rose 28.87% to Rs 771.20 crore in Q2 September 2016 over Q2 September 2015. Revenue from Africa, Asia and CIS region rose 20.38% to Rs 253.84 crore in Q2 September 2016 over Q2 September 2015. Glenmark Europes operations revenue fell 16% to Rs 134.69 crore in Q2 September 2016 over Q2 September 2015. Glenmarks revenue from its Latin American and Caribbean operations fell 19.24% to Rs 133.79 crore in Q2 September 2016 over Q2 September 2015.

Revenue from sale of API to regulated and semi-regulated markets globally rose 33.74% to Rs 221.34 crore in Q2 September 2016 over Q2 September 2015. Glenmark filed two US DMF during the quarter. The good growth was contributed by sale of Lercanidipine, Adapalene, Amiodarone.

Glenmark Pharmaceuticals (GPL) is a research-driven, global, integrated pharmaceutical company.

Powered by Capital Market - Live News

Shriram City Union Finance scales record high after good Q2 outcome
Oct 28,2016

The announcement was made after market hours yesterday, 27 October 2016.

Meanwhile, the S&P BSE Sensex was down 17.04 points, or 0.06%, to 27,898.86

On BSE, so far 8,101 shares were traded in the counter, compared with an average volume of 3,337 shares in the past one quarter. The stock hit a high of Rs 2,545.80 in intraday trade so far, which is record high for the counter. The stock hit a low of Rs 2,340 so far during the day. The stock hit a 52-week low of Rs 1,336.75 on 18 January 2016. The stock had outperformed the market over the past 30 days till 27 October 2016, rising 6.69% compared with 1.33% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 18.26% as against Sensexs 0.48% decline.

The large-cap company has an equity capital of Rs 65.94 crore. Face value per share is Rs 10.

Shriram City Union Finances assets under management (AUM) rose 17.8% to Rs 21390 crore in Q2 September 2016 over Q2 September 2015. Disbursements rose 23% to Rs 5567 crore in Q2 September 2016 over Q2 September 2015. Net interest income rose 22.3% to Rs 735 crore in Q2 September 2016 over Q2 September 2015.

Shriram City Union Finance is Indias premier financial services company specializing in retail finance. It has a comprehensive range of offerings comprising finance for two wheelers and three wheelers, four wheeler finance (both new and pre-owned passenger and commercial vehicles), personal loans, small business loans, and loan against gold.

Powered by Capital Market - Live News

Indiabulls Ventures allots equity shares
Oct 28,2016

Indiabulls Ventures announced that on 27 October 2016, Indiabulls Ventures (formerly Indiabulls Securities) (n++the Companyn++), has issued and allotted 750 (Seven Hundred Fifty) Equity shares of face value Rs. 2/- each, to an eligible employee upon exeicise of options vested in his favour under n++Indiabulls Ventures Limited Employees Stock Option Scheme - 2008.

Consequent to the said allotment, the paid-up Equity share capital of the Company stands increased to Rs. 58,68,32,804/- divided into 29,34,16,402 Equity shares of face value Rs. 2/- each.

Powered by Capital Market - Live News

Barak Valley Cements announces resignation of company secretary and compliance officer
Oct 28,2016

Barak Valley Cements announced that Divyang Jain has resigned from the post of Company Secretary with effect from closure of working hours of 26 October 2016.

Consequent to his resignation as Company Secretary, Divyang Jain also ceases to be Compliance Officer of the Company. His successor will be appointed within due time and the same shall be intimated to the Stock Exchange(s).

Powered by Capital Market - Live News

DCM Shriram fixes record date for interim dividend
Oct 28,2016

DCM Shriram has fixed 09 November 2016 as the Record Date for the purpose of payment of Interim Dividend and will be paid on before 25 November 2016.

Powered by Capital Market - Live News

Kewal Kiran Clothing to pay 1st interim dividend
Oct 28,2016

Kewal Kiran Clothing announced that first interim dividend of Rs 9 per share for FY 2017 will be paid on or after 16 November 2016.

Powered by Capital Market - Live News

Kewal Kiran Clothing fixes record date for 1st interim dividend
Oct 28,2016

Kewal Kiran Clothing has fixed 09 November 2016 as the Record Date for the purpose of First Interim Dividend.

Powered by Capital Market - Live News

Schneider Electric Infrastructure to hold board meeting
Oct 28,2016

Schneider Electric Infrastructure will hold a meeting of the Board of Directors of the Company on 11 November 2016 to approve, the Companys Unaudited Financial Results of the Company for the Quarter ended September 30, 2016.

Powered by Capital Market - Live News

Spentex Industries to hold board meeting
Oct 28,2016

Spentex Industries will hold a meeting of the Board of Directors of the Company on 11 November 2016 to consider and approve Unaudited Financial Results of the Company for the half year ended September 30, 2016.

Powered by Capital Market - Live News